1. Home
  2. TNGX vs SFHG Comparison

TNGX vs SFHG Comparison

Compare TNGX & SFHG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNGX
  • SFHG
  • Stock Information
  • Founded
  • TNGX 2014
  • SFHG 1993
  • Country
  • TNGX United States
  • SFHG Hong Kong
  • Employees
  • TNGX N/A
  • SFHG N/A
  • Industry
  • TNGX Biotechnology: Pharmaceutical Preparations
  • SFHG Publishing
  • Sector
  • TNGX Health Care
  • SFHG Consumer Discretionary
  • Exchange
  • TNGX Nasdaq
  • SFHG Nasdaq
  • Market Cap
  • TNGX 317.4M
  • SFHG 15.4M
  • IPO Year
  • TNGX N/A
  • SFHG 2024
  • Fundamental
  • Price
  • TNGX $1.10
  • SFHG $0.74
  • Analyst Decision
  • TNGX Strong Buy
  • SFHG
  • Analyst Count
  • TNGX 7
  • SFHG 0
  • Target Price
  • TNGX $12.33
  • SFHG N/A
  • AVG Volume (30 Days)
  • TNGX 542.7K
  • SFHG 72.3K
  • Earning Date
  • TNGX 05-12-2025
  • SFHG 06-21-2025
  • Dividend Yield
  • TNGX N/A
  • SFHG N/A
  • EPS Growth
  • TNGX N/A
  • SFHG N/A
  • EPS
  • TNGX N/A
  • SFHG N/A
  • Revenue
  • TNGX $42,069,000.00
  • SFHG $19,760,935.00
  • Revenue This Year
  • TNGX N/A
  • SFHG N/A
  • Revenue Next Year
  • TNGX N/A
  • SFHG N/A
  • P/E Ratio
  • TNGX N/A
  • SFHG N/A
  • Revenue Growth
  • TNGX 15.17
  • SFHG 30.89
  • 52 Week Low
  • TNGX $1.11
  • SFHG $0.55
  • 52 Week High
  • TNGX $12.02
  • SFHG $24.00
  • Technical
  • Relative Strength Index (RSI)
  • TNGX 33.44
  • SFHG N/A
  • Support Level
  • TNGX $1.38
  • SFHG N/A
  • Resistance Level
  • TNGX $1.56
  • SFHG N/A
  • Average True Range (ATR)
  • TNGX 0.16
  • SFHG 0.00
  • MACD
  • TNGX -0.01
  • SFHG 0.00
  • Stochastic Oscillator
  • TNGX 9.90
  • SFHG 0.00

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.

About SFHG Samfine Creation Holdings Group Limited Ordinary Share

Samfine Creation Holdings Group Ltd operates through its subsidiaries. It is an established one-stop printing service provider which principally provides printing services in Hong Kong and the PRC. It offers a wide range of printed products such as (i) book products, which mainly include children's books, educational books, art books, notebooks, diaries and journals; and (ii) novelty and packaging products, which mainly include handcraft products, book sets, pop-up books, stationery products, products with assembly parts and other specialized products, shopping bags and package boxes.

Share on Social Networks: